The Global Prostate Cancer Diagnostics Market Report predicts a steady expansion of the industry at a CAGR of 5.3% by 2022.
The market is expected to reach from $823.5 million in 2017 to $1,000 million by 2022, according to KSU – The Sentinel Newspaper.
Undeniably, there has been a significant increase in the diagnosis and screening of prostate in recent years. In fact, scientists are developing new prostate cancer treatments considering the scope of the diagnostic approach.
Many medical organizations have been scanning key criteria associated with a diagnosis of prostate cancer, tracking parameters such as the age of the patient, ethnicity, family medical history, and diet, according to KSU.
There has also been a rise in funding in the development of new drugs given the advancements in technology for developing newer techniques for diagnosing prostate cancer, which could influence the growth of the global prostate cancer diagnostics market.
The Global Prostate Cancer Diagnostics Market Report is now available at Fact.MR, an independent, pure-play market intelligence firm incorporated to deliver high-quality, customized market research solutions that help our clients successfully go to the market equipped with actionable insights capable of impacting crucial business decisions.
Fact.MR estimates that in terms of revenues, the market will be more lucrative in North America than other regions, while in Asia-Pacific, excluding Japan, it is expected to register the fastest expansion through 2022.
On the other hand, the market in the Middle East and Africa will register a sluggish expansion during the forecast period, according to Fact.MR.
Meanwhile, it is estimated that PSA (prostate-specific antigen) tests will continue to be the largest screening and diagnostic tests of prostate cancer across the globe.
Although hospital-associated labs are expected to remain the largest end-users, revenues from them are expected to register the lowest CAGR by 2022. The Global Prostate Cancer Diagnostics Market Report also mentions key players in the industry, such as AstraZeneca Abbott Laboratories, Bayer Becton, Dickinson and Company, Foundation Medicine, Inc., Cancer Genetics, among others.
